Amgen regulatory affairs director
Executive Summary
Former FDA Office of Cellular, Tissues & Gene Therapies Acting Director Philip Noguchi, MD, joins Amgen. Noguchi will be regulatory affairs director, responsible for the company's regulatory and clinical development policy. Also joining Amgen's Washington D.C. office is former Baxter VP-Government Affairs & Public Policy Jonathon Spear. Spear will be VP-public policy and will work to define strategic public policy options...
You may also be interested in...
CBER cell therapies office director
FDA names former Intronn COO Edward Otto, PhD, director of the Center for Biologics Evaluation & Research Office of Cellular, Tissue & Gene Therapies, effective Nov. 14. Deputy Director Joyce Frey-Vasconcells, PhD, has served as acting director of CBER's cell therapies office since May after Acting Director Phil Noguchi, MD, moved temporarily to the Office of Orphan Products Development. Noguchi left FDA at the end of August to join Amgen (1"The Pink Sheet" Sept. 27, 2004, In Brief)...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.